Free Trial

Legend Biotech (LEGN) Stock Forecast & Price Target

$59.67
-0.21 (-0.35%)
(As of 07/24/2024 ET)

Legend Biotech - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 14 Wall Street analysts who have issued ratings for Legend Biotech in the last 12 months, the stock has a consensus rating of "Buy." Out of the 14 analysts, 14 have given a buy rating for LEGN.

Consensus Price Target

$81.31
36.27% Upside
High Forecast$94.00
Average Forecast$81.31
Low Forecast$60.00

According to the 14 analysts' twelve-month price targets for Legend Biotech, the average price target is $81.31. The highest price target for LEGN is $94.00, while the lowest price target for LEGN is $60.00. The average price target represents a forecasted upside of 36.27% from the current price of $59.67.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$81.31$81.67$83.26$80.90
Forecasted Upside36.27% Upside51.99% Upside34.33% Upside25.23% Upside
Get Legend Biotech Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.

LEGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LEGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Legend Biotech Stock vs. The Competition

TypeLegend BiotechMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside35.80% Upside2,973.08% Upside9.26% Upside
News Sentiment RatingPositive News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/18/2024Scotiabank
5 of 5 stars
 Boost TargetSector Outperform ➝ Sector Outperform$65.00 ➝ $70.00+20.19%
7/18/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$73.00 ➝ $73.00+32.73%
7/15/2024TD Cowen
4 of 5 stars
 Lower TargetBuy ➝ Buy$71.00 ➝ $67.00+23.25%
7/3/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$90.00 ➝ $90.00+101.16%
6/21/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$86.00 ➝ $86.00+109.81%
6/17/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00+113.57%
6/17/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Goonewardene
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$88.00+107.30%
5/23/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$60.00+40.85%
4/3/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$82.00+45.31%
3/18/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$76.00 ➝ $81.00+24.98%
3/13/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$86.00+32.04%
1/24/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$93.00 ➝ $94.00+56.41%
11/6/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$90.09+36.56%
8/2/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
7/20/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$65.00 ➝ $85.00+13.11%
6/12/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$85.00 ➝ $90.00+31.79%
5/25/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$64.00-3.09%
5/22/2023Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
4/19/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$65.00 ➝ $76.00+21.60%
11/1/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
11/1/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
10/31/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:26 PM ET.

LEGN Forecast - Frequently Asked Questions

What is Legend Biotech's forecast for 2024?

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Legend Biotech is $81.31, with a high forecast of $94.00 and a low forecast of $60.00.

Should I buy or sell Legend Biotech stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last twelve months. There are currently 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LEGN shares.

Does Legend Biotech's stock price have much upside?

According to analysts, Legend Biotech's stock has a predicted upside of 52.55% based on their 12-month stock forecasts.

What analysts cover Legend Biotech?

Legend Biotech has been rated by research analysts at BMO Capital Markets, Deutsche Bank Aktiengesellschaft, HC Wainwright, Piper Sandler, Royal Bank of Canada, Scotiabank, TD Cowen, and Truist Financial in the past 90 days.

Do Wall Street analysts like Legend Biotech more than its competitors?

Analysts like Legend Biotech more than other "medical" companies. The consensus rating for Legend Biotech is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LEGN compares to other companies.


This page (NASDAQ:LEGN) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners